Table 2.
Uni- and multivariable regression analysis for significant determinants of plasma renin activity in the total study population.
| Univariable |
Multivariable |
|||||
|---|---|---|---|---|---|---|
| Beta | S.E. | p | Beta | S.E. | p | |
| Age (years) | 0.12 | 0.10 | 0.199 | |||
| Male gender | ||||||
| Left ventricular ejection fraction (%) | −0.31 | 0.07 | <0.001 | −0.13 | 0.08 | 0.12 |
| Heart rate (bpm) | −0.06 | 0.10 | 0.544 | |||
| Mean arterial pressure (mmHg) | −0.51 | 0.11 | <0.001 | −0.44 | 0.09 | <0.001 |
| ACE-i/ARB dose (% of guideline recommended dose) | 0.54 | 0.10 | <0.001 | 0.40 | 0.12 | 0.001 |
| Beta-blocker dose (% of guideline recommended dose) | 0.37 | 0.10 | <0.001 | −0.25 | 0.13 | 0.058 |
| MRA dose (% of guideline recommended dose) | 0.50 | 0.09 | <0.001 | 0.24 | 0.12 | 0.041 |
| Loop diuretic dose (mg bumetanide equivalents) | 0.16 | 0.10 | 0.107 | |||
| Creatinine (mg/dl) | 0.19 | 0.09 | 0.047 | 0.10 | 0.09 | 0.288 |
| NT-proBNP (ng/l) | −0.05 | 0.10 | 0.576 | |||
To correct for non-normal distribution, PRA was logarithmically transformed. Beta and standard error (S.E.) for continuous variables reported per standard deviation change. ACE-i: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; bpm: beats per minute; MRA: mineralocorticoid receptor antagonist; NT-proBNP: N-terminal of the prohormone of B-type natriuretic peptide.